Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients

Journal of Lipid Research

Volumn 49, Issue 6, 2008, Pages 1344-1352

  Bloedon, LeAnne T ^a   Dunbar, Richard ^a   Duffy, Danielle ^a   Pinell Salles, Paula ^a   Norris, Robert ^b   DeGroot, Bruce J ^c   Movva, Rajesh ^b   Navab, Mohamad ^d   Fogelman, Alan M ^d   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PENNSYLVANIA HOSPITAL   (United States)

^c MDS Inc   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; HDL cholesterol; Inflammation

Indexed keywords

APOLIPOPROTEIN A1; ASPARTYLTRYPTOPHYLPHENYLALANYLLYSYLALANYLPHENYLALANYLTYROSYL ASPARTYLLYSYLVALYLALANYLGLUTAMYLLYSYLPHENYLALANYLLYSYLGLUTAMYLALANYL PHENYLALANINAMIDE; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN; PEPTIDE DERIVATIVE; PLACEBO; UNCLASSIFIED DRUG; PEPTIDE;

ADULT; AGED; AORTA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CARDIOVASCULAR RISK; CAROTID ARTERY BRUIT; CLINICAL ARTICLE; CONTROLLED STUDY; CONTUSION; COUGHING; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; ENDOTHELIUM CELL; FEMALE; HEART MURMUR; HEART RATE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INJURY; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LOOSE FECES; LOW FAT DIET; MALE; PERIPHERAL EDEMA; PHARMACODYNAMICS; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SORE THROAT; TREMOR; VOMITING; AMINO ACID SEQUENCE; CARDIOVASCULAR DISEASE; CHEMISTRY; DOSE RESPONSE; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; MOLECULAR MIMICRY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; AMINO ACID SEQUENCE; APOLIPOPROTEIN A-I; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; PEPTIDES;

EID: 48549103014     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P800003-JLR200     Document Type: Article

References (32)

1. Kwiterovich, P. O., Jr. 1998. The antiatherogenic role of high-density lipoprotein cholesterol. Am. J. Cardiol. 82: 13Q-21Q.
2. Rader, D. J. 2006. Molecular regulation of HDL metabolism and function: implications for novel therapies. J. Clin. Invest. 116: 3090-3100.
3. Barter, P. J., S. Nicholls, K. A. Rye, G. M. Anantharamaiah, M. Navab, and A. M. Fogelman. 2004. Antiinflammatory properties of HDL. Circ. Res. 95: 764-772.
4. Moore, R. E., M. A. Kawashiri, K. Kitajima, A. Secreto, J. S. Millar, D. Pratico, and D. J. Rader. 2003. Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor. Arterioscler. Thromb. Vasc. Biol. 23: 1914-1920.
5. Badimon, J. J., L. Badimon, and V. Fuster. 1990. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. 85: 1234-1243.
6. Benoit, P., F. Emmanuel, J. M. Caillaud, L. Bassinet, G. Castro, P. Gallix, J. C. Fruchart, D. Branellec, P. Denefle, and N. Duverger. 1999. Somatic gene transfer of human apoA-I inhibits atherosclerosis progression in mouse models. Circulation. 99: 105-110. (Pubitemid 29035964)
7. Plump, A., C. Scott, and J. Breslow. 1994. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. U.S.A. 91: 9607-9611.
8. Nissen, S. E., T. Tsunoda, E. M. Tuzcu, P. Schoenhagen, C. J. Cooper, M. Yasin, G. M. Eaton, M. A. Lauer, W. S. Sheldon, and C. L. Grines, et al. 2003. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 290: 2292-2300. (Pubitemid 37430562)
9. Navab, M., G. M. Anantharamaiah, S. T. Reddy, S. Hama, G. Hough, V. R. Grijalva, N. Yu, B. J. Ansell, G. Datta, and D. W. Garber, et al. 2005. Apolipoprotein A-I mimetic peptides. Arterioscler. Thromb. Vasc. Biol. 25: 1325-1331.
10. Anantharamaiah, G. M., V. K. Mishra, D. W. Garber, G. Datta, S. P. Handattu, M. N. Palgunachari, M. Chaddha, M. Navab, S. T. Reddy, and J. P. Segrest, et al. 2007. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J. Lipid Res. 48: 1915-1923. (Pubitemid 47360611)
11. Navab, M., G. M. Anantharamaiah, S. T. Reddy, and A. M. Fogelman. 2006. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat. Clin. Pract. Cardiovasc. Med. 3: 540-547.
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2001. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285: 2486-2497.
13. Ansell, B. J., M. Navab, S. Hama, N. Kamranpour, G. Fonarow, G. Hough, S. Rahmani, R. Mottahedeh, R. Dave, and S. T. Reddy, et al. 2003. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 108: 2751-2756. (Pubitemid 37498976)
14. Navab, M., S. S. Imes, S. Y. Hama, G. P. Hough, L. A. Ross, R. W. Bork, A. J. Valente, J. A. Berliner, D. C. Drinkwater, and H. Laks, et al. 1991. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest. 88: 2039-2046.
15. Van Lenten, B. J., A. C. Wagner, M. Navab, G. M. Anantharamaiah, S. Hama, S. T. Reddy, and A. M. Fogelman. 2007. Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J. Lipid Res. 48: 2344-2353. (Pubitemid 350058746)
16. Navab, M., G. M. Anantharamaiah, S. T. Reddy, S. Hama, G. Hough, V. R. Grijalva, A. C. Wagner, J. S. Frank, G. Datta, and D. Garber, et al. 2004. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 109: 3215-3220.
17. Gordon, D. J., and B. M. Rifkind. 1989. High-density lipoproteins- the clinical implications of recent studies. N. Engl. J. Med. 321: 1311-1316.
18. Kastelein, J. J., S. I. van Leuven, L. Burgess, G. W. Evans, J. A. Kuivenhoven, P. J. Barter, J. H. Revkin, D. E. Grobbee, W. A. Riley, and C. L. Shear, et al. 2007. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med. 356: 1620-1630.
19. Nissen, S. E., J. C. Tardif, S. J. Nicholls, J. H. Revkin, C. L. Shear, W. T. Duggan, W. Ruzyllo, W. B. Bachinsky, G. P. Lasala, and E. M. Tuzcu. 2007. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356: 1304-1316.
20. Navab, M., G. M. Ananthramaiah, S. T. Reddy, B. J. Van Lenten, B. J. Ansell, G. C. Fonarow, K. Vahabzadeh, S. Hama, G. Hough, N. Kamranpour, et al. 2004. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J. Lipid Res. 45: 993-1007. (Pubitemid 38679495)
21. Navab, M., S. Y. Hama, G. P. Hough, G. Subbanagounder, S. T. Reddy, and A. M. Fogelman. 2001. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J. Lipid Res. 42: 1308-1317. (Pubitemid 32744255)
22. Navab, M., S. Y. Hama, C. J. Cooke, G. M. Anantharamaiah, M. Chaddha, L. Jin, G. Subbanagounder, K. F. Faull, S. T. Reddy, and N. E. Miller, et al. 2000. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J. Lipid Res. 41: 1481-1494.
23. Navab, M., S. Y. Hama, G. M. Anantharamaiah, K. Hassan, G. P. Hough, A. D. Watson, S. T. Reddy, A. Sevanian, G. C. Fonarow, and A. M. Fogelman. 2000. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J. Lipid Res. 41: 1495-1508.
24. Van Lenten, B. J., A. C. Wagner, G. M. Anantharamaiah, D. W. Garber, M. C. Fishbein, L. Adhikary, D. P. Nayak, S. Hama, M. Navab, and A. M. Fogelman. 2002. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation. 106: 1127-1132. (Pubitemid 34970855)
25. Van Lenten, B. J. 1995. Antiinflammatory HDL becomes proinflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96: 2758-2767.
26. McMahon, M., J. Grossman, J. FitzGerald, E. Dahlin-Lee, D. J. Wallace, B. Y. Thong, H. Badsha, K. Kalunian, C. Charles, and M. Navab, et al. 2006. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 54: 2541-2549. (Pubitemid 44205015)
27. Charles-Schoeman, C., D. Khanna, D. E. Furst, M. McMahon, S. T. Reddy, A. M. Fogelman, H. E. Paulus, G. S. Park, T. Gong, and B. J. Ansell. 2007. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J. Rheumatol. 34: 1459-1464. (Pubitemid 47067979)
28. Roberts, C. K., C. Ng, S. Hama, A. J. Eliseo, and R. J. Barnard. 2006. Effect of a short-term diet and exercise intervention on inflammatory/ anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. J. Appl. Physiol. 101: 1727-1732.
29. Kalantar-Zadeh, K., J. D. Kopple, N. Kamranpour, A. M. Fogelman, and M. Navab. 2007. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int. 72: 1149-1156. (Pubitemid 47609043)
30. Opole, I. O., J. M. Belmont, A. Kumar, and P. M. Moriarty. 2007. Effect of low-density lipoprotein apheresis on inflammatory and noninflammatory high-density lipoprotein cholesterol. Am. J. Cardiol. 100: 1416-1418.
31. Fogelman, A. M. 2005. When pouring water on the fire makes it burn brighter. Cell Metab. 2: 6-8. (Pubitemid 43239820)
32. Navab, M., G. M. Anantharamaiah, S. Hama, D. W. Garber, M. Chaddha, G. Hough, R. Lallone, and A. M. Fogelman. 2002. Oral administration of an apo A-I mimetic peptide synthesized from Damino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 105: 290-292. (Pubitemid 34106174)